SIETES :: 92261 citas

Resultados de la búsqueda por TOPIRAMATO REFINAR BÚSQUEDA

1.

Pennel PB. Prescribing antiepileptic drugs to women of reproductive age. Lancet Neurol 2018:1. [Ref.ID 102517]

2.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F, for the EURAP study group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018:1. [Ref.ID 102516]

3.

Varadkar S. Cannabidiol for drop seizures in Lennox-Gastaut syndrome. Lancet 2018;391:1006-7. [Ref.ID 102474]

4.

Thiele EA, French ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, on behalf of the GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:24 de enero. [Ref.ID 102450]

5.

Bjørk M, Riedel B, Spiqset O, Veiby G, Kolstad E, Daltveit AK, Gilhus NE. Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs In utero. JAMA Neurology 2017:26 de diciembre. [Ref.ID 102193]

6.

Bromley RL, Weston J, Marson AG. Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. JAMA 2017;318:1700-1. [Ref.ID 102140]

7.

Pinto RZ, Verwoerd AJH, Koes BW. Which pain medications are effective for sciatica (radicular leg pain)?. BMJ 2017;359:j4248. [Ref.ID 102095]

8.

Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Benedetto U. Tolerability of new antiepileptic drugs: a network meta-analysis. Eur J Clin Pharmacol 2017;73:811-7. [Ref.ID 101994]

9.

Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD, for the CHAMP Investigators. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med 2017;376:115-24. [Ref.ID 101371]

10.

Anónimo. Topiramate, zonisamide: panilopsies. Prescrire 2016;36:666. [Ref.ID 100822]

11.

Baftiu A, Landmark CJ, Rusten IR, Feet SA, Johannessen SI, Larsson PG. Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders - A pharmacoepidemiological study and clinical implications. Eur J Clin Pharmacol 2016;72:1245-54. [Ref.ID 100799]

12.

Anónimo. Pérampanel et épilepsies généralisées réfractaires. Prescrire 2016;36:492-3. [Ref.ID 100550]

13.

Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424-34. [Ref.ID 100458]

14.

Anónimo. Riesgo de miopatía y glaucoma por zonisamida. Butlletí de Farmacovigilància de Catalunya 2015;13:15-6. [Ref.ID 99834]

15.

Anónimo. Diet, drugs, and surgery for weight loss. Med Lett Drugs Ther 2015;57:21-8. [Ref.ID 98856]

16.

Gual A, Miquel L. Nuevas perspectivas para el tratamiento del alcoholismo. Med Clin (Barc) 2015;144:24-5. [Ref.ID 98707]

17.

Ferrer P, Rafaniello C, Sabaté M, Ballarín E, Coma A, Zara C, Capuano A, Rossi F, Laporte JR, Ibáñez L. Cross-national comparison of antiepileptic drug use: Catalonia, Denmark and Norway, 2007-2011. Epidemiology Biostatistics and Public Health 2014;11:e9405-9409. [Ref.ID 98375]

18.

Rueda-Clausen CF, Padwal RS. Pharmacotherapy for weight loss. BMJ 2014;348:g3526. [Ref.ID 98045]

19.

Anónimo. Zonisamide chez les enfants à partir de l'âge de 6 ans. Prescrire 2014;34:410-1. [Ref.ID 97942]

20.

Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass E, Rowe CJ, Garbutt JC. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014;311:1889-900. [Ref.ID 97596]